Axonics Modulation Technologies, Inc. (AXNX): Price and Financial Metrics

Axonics Modulation Technologies, Inc. (AXNX)

Today's Latest Price: $45.79 USD

2.15 (4.93%)

Updated Nov 27 1:00pm

Add AXNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

See all "A" rated Strong Buy stocks

AXNX Stock Price Chart Interactive Chart >

Price chart for AXNX

AXNX Price/Volume Stats

Current price $45.79 52-week high $52.10
Prev. close $43.64 52-week low $15.25
Day low $43.36 Volume 200,700
Day high $45.82 Avg. volume 628,029
50-day MA $47.28 Dividend yield N/A
200-day MA $38.65 Market Cap 1.82B

Axonics Modulation Technologies, Inc. (AXNX) Company Bio

Axonics Modulation Technologies, Inc. is a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation (SNM) solutions. The company focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in 2013 and is headquartered in Irvine, CA.

AXNX Latest News Stream

Event/Time News Detail
Loading, please wait...

AXNX Latest Social Stream

Loading social stream, please wait...

View Full AXNX Social Stream

Latest AXNX News From Around the Web

Below are the latest news stories about Axonics Modulation Technologies Inc that investors may wish to consider to help them evaluate AXNX as an investment opportunity.

Medtronic scores win in patent dispute with Axonics

The USPTO's Patent Trial and Appeal Board ((PTAB)) has rejected a request from Axonics Modulation Technologies ([[AXNX]] +2.2%) for a hearing to challenge the validity of U.S. Patent No. 9,463,324 ('324 patent) held by Medtronic ([[MDT]] +1.8%) covering technology related to implant recharging and temperature control. The PTAB stated that...

Seeking Alpha | September 25, 2020

Axonics next-gen neurostimulator OK'd in Canada

Health Canada has approved Axonics Modulation Technologies' (AXNX) next-generation r-SNM system for the treatment of urinary and bowel dysfunction. The new device needs recharging less frequently (once/month for ~one hour).The FDA approved the product in April....

Seeking Alpha | September 21, 2020

Read More 'AXNX' Stories Here

AXNX Price Returns

1-mo -2.35%
3-mo 8.35%
6-mo 21.78%
1-year 87.74%
3-year N/A
5-year N/A
YTD 65.25%
2019 83.39%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7397 seconds.